AR1005 / ariBio - LARVOL DELTA

Safety and Efficacy of AR1005 in Patients With Lewy Body Disease (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Yonsei University

New P2 trial • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease

Aribio receives IND approval for Phase 2 clinical trial for Lewy body dementia treatment [Google translation] (Asia Economy) - "Aribio recently announced that it received approval for a domestic phase 2 clinical trial (researcher clinical trial) trial plan (IND) for AR1005 from the Ministry of Food and Drug Safety....This phase 2 clinical trial is a researcher clinical trial to confirm effectiveness and safety and will be conducted at a single institution at Severance Hospital, led by Professor Byeong-seok Ye of the Department of Neurology at Severance Hospital as the main researcher. A total of 60 patients will take AR1005 for 20 weeks, and imaging techniques and biomarker research will be conducted to accurately diagnose Lewy body dementia. The plan is to begin recruiting patients at the end of this year and announce the top line clinical results as early as the end of next year."

New P2 trial • CNS Disorders • Dementia • Lewy Body Disease